Ignite Creation Date:
2024-05-06 @ 1:35 AM
Last Modification Date:
2024-10-26 @ 11:06 AM
Study NCT ID:
NCT01841021
Status:
TERMINATED
Last Update Posted:
2017-01-19
First Post:
2013-04-24
Brief Title:
Pilot Study of Brentuximab Vedotin in RelapsedRefractory Peripheral T-Cell Lymphoma Expressing CD30
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Pilot Study of Brentuximab Vedotin in RelapsedRefractory Peripheral T-Cell Lymphoma Expressing CD30 Receptor
Status:
TERMINATED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow accrual loss of sponsor support
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma The side effects unwanted effects of SGN-35 in patients with this certain type of large B-cell lymphoma will also be studied It is not known if brentuximab vedotin is better or worse than other treatment patients might be given
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 35-IST-019 | OTHER_GRANT | Seattle Genetics | None |